Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson's disease

European Journal of Neurology

Volumn 19, Issue 3, 2012, Pages 411-416

  Izawa, M O ^a   Miwa, H ^a   Kajimoto, Y ^a   Kondo, T ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diagnosis; MIBG myocardial scintigraphy; Olfactory dysfunction; Parkinson's disease; Transcranial sonography

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE DURATION; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MALE; MYOCARDIAL PERFUSION IMAGING; NEUROIMAGING; NEUROLOGIC EXAMINATION; NON INVASIVE PROCEDURE; ODOR STICK IDENTIFICATION TEST FOR JAPANESE; OLFACTORY SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENSORY SYSTEM EXAMINATION; SMELLING; SUBSTANTIA NIGRA; TEMPORAL BONE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; OLFACTION DISORDERS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84856836789     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03533.x     Document Type: Article

References (23)

1. Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. J Neurol Neurosurg Psychiatry 2010; 81: 1223-1228.
2. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
3. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008; 7: 417-424.
4. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005; 20: 383-385.
5. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999; 53: 1026-1031.
6. Okawa M, Miwa H, Kajimoto Y, et al. Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 2007; 46: 1527-1531.
7. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002; 59: 999-1005.
8. Stockner H, Sojer M, K KS, et al. Midbrain sonography in patients with essential tremor. Mov Disord 2007; 22: 414-417.
9. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984; 94: 176-178.
10. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002; 249: 1-5.
11. Ponsen MM, Stoffers D, Twisk JW, Wolters E, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord 2009; 24: 1060-1065.
12. Haehner A, Hummel T, Reichmann H. Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev Neurother 2009; 9: 1773-1779.
13. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67: 189-194.
14. Orimo S, Amino T, Ito Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005; 109: 583-588.
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
16. Fahn S, Elton RL. The unified Parkinson's disease rating scale. In: Fahn S, Marsden D, Calne DB, Goldstein M eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Healthcare Information, 1987: 153-163.
17. Kajimoto Y, Miwa H, Okawa-Izawa M, Hironishi M, Kondo T. Transcranial sonography of substantia nigra and MIBG myocardial scintigraphy: complementary role in diagnosis of Parkinson's disease. Parkinsonism Relat Disord 2009; 15: 270-272.
18. Saito S, Ayabe-Kanamura S, Takashima Y, et al. Development of a smell identification test using a novel stick-type odor presentation kit. Chem Senses 2006; 31: 379-391.
19. Oka H, Toyoda C, Yogo M, Mochio S. Olfactory dysfunction and cardiovascular dysautonomia in Parkinson's disease. J Neurol 2010; 257: 969-976.
20. Iwanami M, Miyamoto T, Miyamoto M, Hirata K, Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med 2010; 11: 361-365.
21. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-1202.
22. Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol 2008; 15: 5-13.
23. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604-612.